Eloxx ends long wait for phase 2 cystic fibrosis data. Market shrugsnews2021-11-17T13:09:36+00:00November 17th, 2021|FierceBiotech|
Fine-tuning targeted therapy for multiple myeloma with ‘multi-omics’ datanews2021-11-17T11:48:34+00:00November 17th, 2021|FierceBiotech|
As Merck and Pfizer predict incoming billions from their COVID drugs, Roche culls pandemic ties with Ateanews2021-11-17T09:44:50+00:00November 17th, 2021|FierceBiotech|
Novartis-partnered DARPin flames out in COVID-19 study, sending Molecular Partners’ stock into nosedivenews2021-11-16T13:03:48+00:00November 16th, 2021|FierceBiotech|
UPDATE: Sandrock makes a sharp exit, retiring as Biogen R&D chief amid fallout from Aduhelm approvalnews2021-11-16T10:17:50+00:00November 16th, 2021|FierceBiotech|
Medidata co-founder Glen de Vries dies in plane crash less than a month after Blue Origin flightnews2021-11-15T16:07:31+00:00November 15th, 2021|FierceBiotech|
Injectable ‘dancing molecules’ repair spinal cord injury, restore mobility in paralyzed micenews2021-11-15T14:12:33+00:00November 15th, 2021|FierceBiotech|
Protagonist posts phase 2 hormone replacement data, pitching for lead role in genetic iron overload diseasenews2021-11-15T14:02:54+00:00November 15th, 2021|FierceBiotech|
AHA: AstraZeneca, Moderna shine early light on mRNA potential in heart failurenews2021-11-15T14:01:05+00:00November 15th, 2021|FierceBiotech|
Twist spins out COVID-19 antibody program, forming startup to advance variant-busting candidate news2021-11-15T13:06:46+00:00November 15th, 2021|FierceBiotech|
